EUVIMEDEUVIMED entdecken
Open Access

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

Jingjing Shen iD, Huiqin Gao iD, Linfu Chen iD, Yutong Jiang iD, Shu Li iD, Yu Chao iD, Nanhui Liu iD, Yufei Wang iD, Ting Wei iD, Yan Liu iD, Jipeng Li iD, Muchao Chen iD und 7 weitere

Science Advances · 27.01.2023 · 9 (4)

DOI: 10.1126/sciadv.abq3104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 27.01.2023. Verfasst von Jingjing Shen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow Universit…. Hauptthemen laut MEDLINE: Choroidal Neovascularization. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic antibodies are extensively used to treat fundus diseases by intravitreal injection, as eyedrop formulation has been rather challenging due to the presence of ocular barriers. Here, an innovative penetrating carrier was developed for antibody delivery in eyedrop formulations. We found that fluorocarbon-modified chitosan (FCS) would self-assemble with proteins to form nanocomplexes, which could effectively pass across the complicated ocular structure to reach the posterior eye segments in both mice and rabbits. In a choroidal melanoma–bearing mouse model, eyedrops containing FCS/anti-PDL1 could induce stronger antitumor immune responses than those triggered by intravenous injection of anti-PDL1. Moreover, in choroidal neovascularization–bearing mouse and rabbit models, FCS/anti-VEGFA eyedrops effectively inhibited vascular proliferation, achieving comparable therapeutic responses to those observed with intravitreal injection of anti-VEGFA. Our work presents an effective delivery carrier to treat fundus diseases using eyedrop of therapeutic proteins, which may enable at-home treatment of many eye diseases with great patient compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Choroidal NeovascularizationRabbitsAnimalsMiceOphthalmic SolutionsFundus OculiDisease Models, Animal

Substanzen

Ophthalmic Solutions

Autor:innen und Institutionen

  • Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.
  • Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, P. R. China.
  • Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, P. R. China.
  • Department of Ophthalmology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, 215123 China.

ORCID-Profile: Jingjing Shen, Huiqin Gao, Linfu Chen, Yutong Jiang, Shu Li, Yu Chao, Nanhui Liu, Yufei Wang, Ting Wei, Yan Liu, Jipeng Li, Muchao Chen, Jiafei Zhu, Juan Liang, Xiaoyu Zhou, Xiaofeng Zhang, Ping Gu, Qian Chen, Zhuang Liu

Zitieren

APA

Shen, J., Gao, H., Chen, L., Jiang, Y., Li, S., Chao, Y., Liu, N., Wang, Y., Wei, T., Liu, Y., Li, J., Chen, M., Zhu, J., Liang, J., Zhou, X., Zhang, X., Gu, P., Chen, Q., & Liu, Z. (2023). Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment. Science Advances, 9(4). https://doi.org/10.1126/sciadv.abq3104

Vancouver

Shen J, Gao H, Chen L, Jiang Y, Li S, Chao Y, et al. Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment. Science Advances. 2023;9(4). doi:10.1126/sciadv.abq3104

BibTeX
@article{Shen2023,
  author = {Shen, Jingjing and Gao, Huiqin and Chen, Linfu and Jiang, Yutong and Li, Shu and Chao, Yu and Liu, Nanhui and Wang, Yufei and Wei, Ting and Liu, Yan and Li, Jipeng and Chen, Muchao and Zhu, Jiafei and Liang, Juan and Zhou, Xiaoyu and Zhang, Xiaofeng and Gu, Ping and Chen, Qian and Liu, Zhuang},
  title = {Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {4},
  doi = {10.1126/sciadv.abq3104}
}
Kostenlos starten →